

#5/K.T.  
5/8 B

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name		Cindy Hoang	
Signature		Date	
<i>Cindy Hoang</i>		4/23/02	

AMENDMENT UNDER 37 C.F.R. §1.111		RECEIVED	
<p>Address to: Assistant Commissioner for Patents Washington, D.C. 20231</p>	Attorney Docket Confirmation No.	UCSF085CON2 4958	MAY 06 2002
	First Named Inventor	NADEL	
	Application Number	09/865,239	TECH CENTER 1600/290
	Filing Date	May 24, 2001	
	Group Art Unit	1635	
	Examiner Name	J. Zara	
	Title	PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS	

Sir:

This amendment is responsive to the Office Action dated January 28, 2002, for which a three-month period for response was given making this response due on or before April 28, 2002.

Accordingly, this response is timely filed.

In view of the remarks put forth below, reconsideration and allowance are respectfully requested.

# I. AMENDMENTS

*Allowed claims*

## IN THE CLAIMS

Please enter the amendments to claims 28, 34, and 40, as shown below.

*1 28* (Amended) A pharmaceutical formulation for treatment of airway mucus hypersecretion,

*B<sup>2</sup>* comprising:

a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist that binds to an EGF-R, wherein said amount is effective to reduce airway mucus hypersecretion; and a flowable formulation suitable for delivery by inhalation.

*7 34* (Amended) A package for use in treating airway mucus hypersecretion, comprising a

*B<sup>2</sup>* container having therein a flowable formulation comprising a pharmaceutically active epidermal growth factor receptor (EGF-R) antagonist that binds to an EGF-R, wherein the EGF-R antagonist is present in the formulation in an amount effective to reduce airway mucus hypersecretion.